However, preclinical evidence suggests that inhibition of other pathways such as MEK with cobimetinib leads to upregulation of MHC1 on tumor cells, induces intratumoral T-cell activation, and enhances anti-PD-L1 activity, making the thus far resistant tumors sensitive to immune intervention. The gene discussed is CD274; the disease is neoplasm.